These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 33113408

  • 1. Identification of the hydantoin alkaloids parazoanthines as novel CXCR4 antagonists by computational and in vitro functional characterization.
    Vitale RM, Thellung S, Tinto F, Solari A, Gatti M, Nuzzo G, Ioannou E, Roussis V, Ciavatta ML, Manzo E, Florio T, Amodeo P.
    Bioorg Chem; 2020 Dec; 105():104337. PubMed ID: 33113408
    [Abstract] [Full Text] [Related]

  • 2. Parazoanthines A-E, hydantoin alkaloids from the Mediterranean sea anemone Parazoanthus axinellae.
    Cachet N, Genta-Jouve G, Regalado EL, Mokrini R, Amade P, Culioli G, Thomas OP.
    J Nat Prod; 2009 Sep; 72(9):1612-5. PubMed ID: 19708637
    [Abstract] [Full Text] [Related]

  • 3. Minimalist hybrid ligand/receptor-based pharmacophore model for CXCR4 applied to a small-library of marine natural products led to the identification of phidianidine a as a new CXCR4 ligand exhibiting antagonist activity.
    Vitale RM, Gatti M, Carbone M, Barbieri F, Felicità V, Gavagnin M, Florio T, Amodeo P.
    ACS Chem Biol; 2013 Dec 20; 8(12):2762-70. PubMed ID: 24102412
    [Abstract] [Full Text] [Related]

  • 4. Metabolomic profiling reveals deep chemical divergence between two morphotypes of the zoanthid Parazoanthus axinellae.
    Cachet N, Genta-Jouve G, Ivanisevic J, Chevaldonné P, Sinniger F, Culioli G, Pérez T, Thomas OP.
    Sci Rep; 2015 Feb 06; 5():8282. PubMed ID: 25655432
    [Abstract] [Full Text] [Related]

  • 5. Structural optimization of aminopyrimidine-based CXCR4 antagonists.
    Zhu F, Wang Y, Du Q, Ge W, Li Z, Wang X, Fu C, Luo L, Tian S, Ma H, Zheng J, Zhang Y, Sun X, He S, Zhang X.
    Eur J Med Chem; 2020 Feb 01; 187():111914. PubMed ID: 31806538
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Structure-Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist.
    Di Maro S, Di Leva FS, Trotta AM, Brancaccio D, Portella L, Aurilio M, Tomassi S, Messere A, Sementa D, Lastoria S, Carotenuto A, Novellino E, Scala S, Marinelli L.
    J Med Chem; 2017 Dec 14; 60(23):9641-9652. PubMed ID: 29125295
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis, and evaluation of novel CXCR4 antagonists based on an aminoquinoline template.
    Lin Y, Li Z, Xu C, Xia K, Wu S, Hao Y, Yang Q, Ma H, Zheng J, Luo L, Zhu F, He S, Zhang X.
    Bioorg Chem; 2020 Jun 14; 99():103824. PubMed ID: 32334192
    [Abstract] [Full Text] [Related]

  • 9. Silibinin, a novel chemokine receptor type 4 antagonist, inhibits chemokine ligand 12-induced migration in breast cancer cells.
    Wang Y, Liang WC, Pan WL, Law WK, Hu JS, Ip DT, Waye MM, Ng TB, Wan DC.
    Phytomedicine; 2014 Sep 25; 21(11):1310-7. PubMed ID: 25172795
    [Abstract] [Full Text] [Related]

  • 10. Design, synthesis, and structure-activity-relationship of a novel series of CXCR4 antagonists.
    Li Z, Wang Y, Fu C, Wang X, Wang JJ, Zhang Y, Zhou D, Zhao Y, Luo L, Ma H, Lu W, Zheng J, Zhang X.
    Eur J Med Chem; 2018 Apr 10; 149():30-44. PubMed ID: 29494843
    [Abstract] [Full Text] [Related]

  • 11. Structure-based development of antagonists for chemokine receptor CXCR4.
    Zhang C, Hou T, Feng Z, Li Y.
    Curr Comput Aided Drug Des; 2013 Mar 10; 9(1):60-75. PubMed ID: 22734712
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties.
    Nguyen HH, Kim MB, Wilson RJ, Butch CJ, Kuo KM, Miller EJ, Tahirovic YA, Jecs E, Truax VM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.
    J Med Chem; 2018 Aug 23; 61(16):7168-7188. PubMed ID: 30052039
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Small molecule CXCR4 chemokine receptor antagonists: developing drug candidates.
    Khan A, Greenman J, Archibald SJ.
    Curr Med Chem; 2007 Aug 23; 14(21):2257-77. PubMed ID: 17896975
    [Abstract] [Full Text] [Related]

  • 17. Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in Vitro ADMET Properties.
    Miller EJ, Jecs E, Truax VM, Katzman BM, Tahirovic YA, Wilson RJ, Kuo KM, Kim MB, Nguyen HH, Saindane MT, Zhao H, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.
    J Med Chem; 2018 Feb 08; 61(3):946-979. PubMed ID: 29350534
    [Abstract] [Full Text] [Related]

  • 18. Metabolome consistency: additional parazoanthines from the mediterranean zoanthid parazoanthus axinellae.
    Audoin C, Cocandeau V, Thomas OP, Bruschini A, Holderith S, Genta-Jouve G.
    Metabolites; 2014 May 30; 4(2):421-32. PubMed ID: 24957034
    [Abstract] [Full Text] [Related]

  • 19. An update on small molecules targeting CXCR4 as starting points for the development of anti-cancer therapeutics.
    Grande F, Giancotti G, Ioele G, Occhiuzzi MA, Garofalo A.
    Eur J Med Chem; 2017 Oct 20; 139():519-530. PubMed ID: 28826086
    [Abstract] [Full Text] [Related]

  • 20. The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential.
    Peng D, Cao B, Zhou YJ, Long YQ.
    Eur J Med Chem; 2018 Apr 10; 149():148-169. PubMed ID: 29500940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.